Press Releases
"We do not have the Schiff Report. We do not have any underlying materials to the Schiff Report. We do not know of any hearings other than one of academics and possibly a presentation by Chairman Schiff’s committee. For the first time in history, this Committee will weigh impeachment without any evidence for us to review."
"The Committee must ensure it maintains its credibility and its historically preeminent role in the impeachment of presidents by not rushing to articles of impeachment or hearing only from scholars with demonstrated animosity towards the President. Throughout this hurried and partisan impeachment process, I have consistently requested mere fairness from members of the majority.
"Chairman Schiff has engaged in an assault on the already one-sided process.
"In spite of how important this issue is to consumers and businesses, this committee dragged its feet, and, instead, fixated on going after President Trump in an attempt to undo the 2016 election. That nonsense is now taking place in other committees rather than our own.
"Everyone knows that I believe in a strong patent system — that it’s essential to our economy, creating jobs and keeping America the world’s technology leader. Patents may be most important to the pharmaceutical and biologic industries.
"The Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 strikes a good balance by giving the FTC the clear authority to prosecute cases in which a company has engaged in product hopping, without disincentivizing innovation to improve patient care.
"Growers are increasingly turning to the H-2A visa program to get the temporary labor they need, but the program needs reform. The agricultural industry wants and deserves a streamlined program that provides more certainty as to the temporary labor needed to sustain their businesses.
"With all the marijuana-related bills pending this Congress — including the bipartisan STATES Act — you have unfortunately chosen to markup the MORE Act today. This bill is nearly devoid of bipartisan support, and it fails to address many critical issues surrounding the cultivation, distribution, sale and use of marijuana."
" . . . the Federal Circuit continues to make decisions that illustrate what a mess the U.S. patent system has become. . . . The [Patent Eligibility Test] has upended confidence in patents in all industries from software and biotech innovations to mechanical inventions. Sadly, this begs the question: Are any patents safe from attack on eligibility grounds?
"Innovation and competition in the pharmaceutical market are key to lowering prescription drug costs. Anticompetitive tactics like product hopping are hurting American families, who are struggling to pay for expensive pharmaceuticals.